Online citations, reference lists, and bibliographies.
← Back to Search

A Comparison Of The Spread Of Three Formulations Of Botulinum Neurotoxin A As Determined By Effects On Muscle Function

S. Dodd, B.A. Rowell, I.S. Vrabas, R.J. Arrowsmith, P.J. Weatherill
Published 1998 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The purpose of these experiments was to compare the spread of three formulations of botulinum neurotoxin A. A gelatin/phosphate buffer (C), DysportR (D {0.5 U}, BotoxR (B {0.167 U}), or a purified preparation of botulinum neurotoxin A [Bont A] (BA {0.5 U}) was injected into the tibialis anterior of male, Wistar rats. After 4 days, the adjacent extensor digitorum longus muscle was isolated in situ and the nerve was maximally stimulated to determine contractile properties and the rate of fatigue. There were no differences in body or muscle weights between any of the groups after 4 days of treatment. Maximal twitch and tetanic tensions were decreased ≈ 25% (p < 0.05) in all treatment groups compared to C. In addition, rate of tension development was significantly less in all treatment groups compared to C but one‐half relaxation time and time to peak tension were not different between any groups. Fatigue of the muscle was significantly faster in all groups compared to C but there was no difference between treatment groups. These data indicated that botulinum toxin A injected intramuscularly was likely to spread to adjacent muscles but that the spread was not different between the three formulations tested. The effect of the spread ranged from a slight to a severe reduction in maximal tension but this did not occur in all animals studied.
This paper references
10.1016/0021-9290(91)90322-E
Three-dimensional tissue deformation in subcutaneous tissues overlying bony prominences may help to explain external load transfer to the interstitium.
K. Dodd (1991)
10.1017/S0317167100027748
Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations.
S. Kraft (1988)
10.1016/0303-8467(90)90095-M
Responsiveness of idiopathic spasmodic torticollis to botulinum a toxin injection. a critical evaluation of five cases
Sandro Maurri (1990)
10.1136/jnnp.33.1.40
Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles.
L. Duchen (1970)
10.1002/MUS.880100610
Distant effects of local injection of botulinum toxin
D. Lange (1987)
10.1159/000138673
Ca2+ influx insensitive to organic Ca2+ entry blockers contributes to noradrenaline-induced contractions of the isolated guinea pig aorta.
M. A. Gouw (1990)
10.1097/00002826-199404000-00008
Determining a dose-effect curve for botulinum toxin in the sternocleidomastoid muscle in cervical dystonia
A. Buchman (1994)
10.1016/S0140-6736(94)91806-6
Dose standardisation of botulinum toxin
A. Pickett (1994)
10.1136/jnnp.59.1.102
Dose standardisation of botulinum toxin.
M. Marion (1995)
10.1016/0021-9290(91)90382-W
The determinants of skeletal muscle force and power: their adaptability with changes in activity pattern.
R. Fitts (1991)
10.1212/WNL.40.2.277
Botulinum toxin injections for cervical dystonia
J. Jankovic (1990)
10.1146/ANNUREV.BB.04.060175.001033
Muscle filament structure and muscle contraction.
J. Squire (1975)
10.1288/00005537-199502000-00006
The effect of botulinum toxin type a injection on compound muscle action potential in an in vivo rat model
J. Cichon (1995)
Potency equivalence of botulinum toxin preparations.
P. Hambleton (1994)
10.1038/307457A0
Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization
J. O. Dolly (1984)
10.1093/BRAIN/118.2.533
Botulinum toxin-induced myopathy in the rat.
S. M. Hassan (1995)
10.1212/WNL.36.4.545
Botulinum toxin for blepharospasm: single-fiber EMG studies
D. Sanders (1986)



This paper is referenced by
10.1155/2013/686329
Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis
H. E. El Kahky (2013)
10.1007/978-3-540-34095-9
Botulinum Toxin in Aesthetic Medicine
B. Rzany (2007)
10.1111/jocd.12949
Two different types of botulinum toxins: Is there a difference in efficacy and longevity?
Debraj Shome (2019)
10.1080/14764170802094282
Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications
A. Pickett (2008)
10.1007/978-1-4939-0261-3
Clinical Applications of Botulinum Neurotoxin
K. Foster (2014)
10.1517/14656566.2.12.1985
Botulinum toxin for the treatment of cervical dystonia
J. Jankovic (2001)
10.1007/978-3-540-34095-9_6
Advanced Indications and Techniques
M. D. Maio (2007)
10.1159/000069495
A Double-Blind Randomised Placebo-Controlled Evaluation of Three Doses of Botulinum Toxin Type A (Dysport®) in the Treatment of Spastic Equinovarus Deformity after Stroke
S. Pittock (2003)
10.1111/j.1468-1331.2009.02723.x
Botulinum toxin B increases mouth opening in patients with spastic trismus
U. Fietzek (2009)
10.2147/OPTH.S13978
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm
J. Park (2011)
10.1016/j.jaapos.2007.11.001
Botulinum toxin pretreatment augments the weakening effect of injection with ricin-mAb35 in rabbit extraocular muscle.
S. Christiansen (2008)
10.2147/RRBC.S60432
The botulinum toxin as a therapeutic agent: molecular and pharmacological insights
R. Kukreja (2015)
10.1016/j.pmrj.2017.04.014
Detection of Botulinum Toxin Muscle Effect in Humans Using Magnetic Resonance Imaging: A Qualitative Case Series
M. O'dell (2017)
10.1007/BF03033931
Botulinum neurotoxin — from laboratory to bedside
K. Foster (2009)
10.1016/j.toxicon.2008.06.021
The in vivo rat muscle force model is a reliable and clinically relevant test of consistency among botulinum toxin preparations.
Andy M Pickett (2008)
10.2147/NDT.S16085
A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins
J. Jimenez-Shahed (2012)
10.1002/mds.25582
Diffusion, spread, and migration of botulinum toxin
Juan Ramirez-Castaneda (2013)
10.1002/mus.21343
Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg
L. Carli (2009)
10.1177/1090820X13480479
Consensus panel's assessment and recommendations on the use of 3 botulinum toxin type A products in facial aesthetics.
Z. P. Lorenc (2013)
10.1007/S40277-013-0012-9
Análisis de impacto presupuestario del uso de la toxina botulínica tipo A (TBA) en el Sistema Nacional de Salud en España
Gloria Tapias (2013)
10.1016/B978-1-4160-4928-9.00032-9
Chapter 32 – Properties of Pharmaceutical Products of Botulinum Neurotoxins
H. Bigalke (2009)
10.1097/01.prs.0000244311.72941.9a
Botulinum Toxin in Facial Palsy: An Effective Treatment for Contralateral Hyperkinesis
M. de Maio (2007)
10.2147/BTT.S65603
Botulinum toxin type A products are not interchangeable: a review of the evidence
M. Brin (2014)
10.1631/jzus.B1300021
Influence of injection of Chinese botulinum toxin type A on the histomorphology and myosin heavy chain composition of rat gastrocnemius muscles
B. Hong (2013)
10.1016/J.TOXICON.2005.03.022
Botulinum neurotoxin type A causes shifts in myosin heavy chain composition in muscle.
S. Dodd (2005)
10.2147/BTT.S14902
Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?
J. Frevert (2010)
10.3390/toxins9110352
Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles: Special Considerations
M. Alimohammadi (2017)
10.1002/mds.22336
Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double‐blind study
G. Kranz (2009)
10.1007/978-1-4939-0261-3_2
Botulinum Toxin as a Clinical Product: Manufacture and Pharmacology
A. Pickett (2014)
10.1177/1090820X12474633
IncobotulinumtoxinA (Xeomin): background, mechanism of action, and manufacturing.
Z. P. Lorenc (2013)
Semantic Scholar Logo Some data provided by SemanticScholar